The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peng, S. L.
Right arrow Articles by Craft, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peng, S. L.
Right arrow Articles by Craft, J.
The Journal of Immunology, 1998, 160: 652-660.
Copyright © 1998 by The American Association of Immunologists

Perforin Protects Against Autoimmunity in Lupus-Prone Mice1

Stanford L. Peng*,{ddagger}, Javid Moslehi*, Marie E. Robert{dagger} and Joe Craft2,*

* Section of Rheumatology and {dagger} Department of Pathology, Yale University School of Medicine, and {ddagger} Department of Biology, Yale University, New Haven, CT 06510


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The roles of cytolytic regulatory mechanisms in the immune system of lupus-prone mice were examined in perforin-deficient animals bearing functional or defective (lpr) Fas Ag (CD95). Perforin-deficient Fas+ animals developed accelerated autoimmunity, characterized by increased hypergammaglobulinemia, autoantibody production, and immune deposit-related end-organ disease compared with perforin-intact counterparts. In comparison, perforin-deficient lpr animals had accelerated mortality compared with perforin-intact lpr mice, associated with the abnormal accumulation of CD3+CD4-CD8- {alpha}ß T cells in conjunction with unaltered hypergammaglobulinemia, autoantibody production, and immune complex renal disease. These results indicate that cytolytic lymphoid regulation plays critical roles in the immune homeostasis of lupus-prone animals, and identify perforin-mediated cytotoxicity as a specific mechanism in the regulation of systemic autoimmunity.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
MRL/Mp-lpr/lpr (MRL/lpr) mice spontaneously develop a severe autoimmune syndrome closely resembling systemic lupus erythematosus, characterized by hypergammaglobulinemia, autoantibody production, lymphadenopathy, and end-organ disease associated with immune complex formation (1). Their lymphadenopathy consists of a nonmalignant lymphoaccumulation of CD4-CD8-B220+ T cells (2), a consequence of defective activation-induced cell death (3, 4, 5, 6) secondary to functional Fas (CD95) deficiency (7, 8, 9, 10, 11). End-organ disease includes both hepatic (12) and salivary gland (13) lesions, but renal disease, characterized by glomerulonephritis, interstitial nephritis, and perivasculitis (14, 15, 16), has been examined most intensely, and has been linked to an immune complex pathogenesis (14, 17, 18).

Several studies have established that MRL lupus is driven by pathogenic CD4+ {alpha}ß T cells that provide help to autoreactive B cells (19, 20, 21). A more complex dysregulation of the immune system, however, in which both pathogenic and down-regulatory T cells compete for control of autoimmunity, is most likely associated with disease pathogenesis (22). Proposed regulatory mechanisms include cytokine-mediated modulation of immune responses, such as the skewing of Th1- vs Th2-dominated environments (23), but most studies have indicated pathogenic roles for several cytokines in murine lupus, including IFN-{gamma}, IL-4, IL-6, IL-10, and IL-12 (24, 25, 26, 27, 28, 29, 30). On the other hand, T cells may directly regulate pathogenic lymphocytes by cytotoxicity, as suggested by the Fas-mediated regulation of some activated T cells and B cells (31, 32, 33). Indeed, more recent work in MRL lupus has suggested that {gamma}{delta} T cells regulate pathogenic {alpha}ß T cells (34), while {gamma}{delta} T cells and subsets of regulatory {alpha}ß T cells regulate B cells (22, 34, 35), via both Fas-dependent and Fas-independent mechanisms (34, 35, 36).

Other than Fas, potential regulatory mechanisms in lupus include TNF and perforin (pfp);3 together, these three mediate the majority of cytotoxic lymphocyte responses (37). A role for TNF in the down-regulation of lupus has been strongly suggested by the exacerbation of disease in TNF receptor-deficient lpr animals (12); however, the regulatory role of pfp in systemic autoimmunity is unknown, despite its critical role in lymphocyte-mediated cytotoxicity (38, 39, 40, 41). Instead, investigations in murine lupus have focused upon the potential pathogenic role of pfp: one in MRL/lpr mice described the constitutive, functional expression of pfp by the expanded CD4-CD8- T cells (42), and two studies in New Zealand mice demonstrated the steroid-sensitive expression of pfp in T cells from disease lesions (43, 44).

The circumstantial evidence implicating a regulatory role for pfp in murine lupus (34, 35, 36) suggested that pfp deficiency may exacerbate, rather than ameliorate, murine lupus. To explore this possibility, pfp-deficient lupus-prone animals were generated by crossing pfp-/- mice (41) with MRL/lpr breeders. Pfp-deficient Fas+ animals developed accelerated autoimmune disease compared with pfp-intact Fas+ counterparts, characterized by increased hypergammaglobulinemia, autoantibody production, and end-organ disease. In comparison, in lpr animals pfp deficiency caused early mortality associated wtih T cell lymphoaccumulation reminiscent of lpr-related lymphoproliferative disease. These results demonstrate that pfp plays essential roles in the regulation of both humoral autoimmunity and lymphoid regulation, and emphasize the critical role of cytotoxicity in the modulation of systemic autoimmunity.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice

Pfp-/- (C57BL/6 x 129/Sv) mice (41) (Taconic, Germantown, NY) were crossed against MRL/lpr breeders (The Jackson Laboratory, Bar Harbor, ME) to generate pfp+/- Fas+/lpr double-heterozygotic offspring, which were intercrossed to generate pfp-intact (pfp+) and pfp-deficient (pfp-) Fas-intact (Fas+) or lpr/lpr (lpr) F2 animals. Genotypes were screened via PCR of tail DNA, using primers PFP451F (5'-GCCTACCTGTGGCAATCACCCACTG), PFP670R (5'-TCAGCTGCAAAATTGGCTACCTTGG), and NEOMS1 (45) (5'-CCTTGCGCAGCTGTGCTCGACGTTG). The PFP451F-PFP670R combination yielded a 219-bp fragment corresponding to the wild-type allele, while the PFP451F-NEOMS1 combination yielded an approximately 720-bp fragment corresponding to the mutant allele (not shown). Fas genotype was also determined by PCR, as described elsewhere (3). All animals were maintained under specific pathogen-free conditions at Yale University School of Medicine (New Haven, CT).

Cytotoxicity assays

To assay cytotoxic activities in vitro, NK cell-enriched splenocytes were used as effectors against 51Cr-labeled YAC-1 targets (46). Briefly, twice-washed, erythrocyte-cleared splenocytes were passed through a prewarmed, prewetted nylon wool column, incubated at 37°C for 45 min. NK effectors were prepared from nonadherent cells, which were expanded for 48 h at 2 x 106 cells/ml in DMEM (Life Technologies, Gaithersburg, MD) containing 10% FCS and 500 U/ml of mouse rIL-2 (Sigma Chemical Co., St. Louis, MO). YAC-1 targets (TIB-160; American Type Culture Collection, Rockville, MD) were labeled for 2 h with 100 µCi of Na51CrO4 (Amersham Life Science Corp., Arlington Heights, IL), washed thrice, and resuspended in DMEM containing 10% FCS. A quantity amounting to 5 x 103 labeled target cells in 100 µl was mixed with an equal volume of effector cells at varying ratios in a round-bottom 96-well plate (Falcon 3077; Becton Dickinson, Lincoln Park, NJ). Cells were centrifuged at 100 x g to ensure contact, incubated for 4 h at 37°C, 5% CO2/air atmosphere, and then centrifuged again at 100 x g. One hundred microliters of supernatant were assayed for 51Cr release by standard gamma counter.

Ab analyses

Serum Ig and autoantibody studies were performed as previously described (35). Briefly, antinuclear Abs were assayed by indirect immunofluorescence (FANA) on sera diluted at 1/50 using HEp-2 substrate cells (Quidel, San Diego, CA). Fluorescence was visualized with a Zeiss Axioskop microscope at x1000 magnification, with intensity rated 0 to 4+, as determined by the light meter’s estimated required exposure time for 10 to 12 cells per high power field on ASA 400 film (>120 s, 0; <120 s, 1+; <60 s, 2+; <30 s, 3+; <15 s, 4+). Specific autoantibody titers (IgG anti-dsDNA, IgG anti-small nuclear ribonucleoprotein (snRNP), and {kappa} rheumatoid factor) were determined by ELISA using specific substrates on sera at 1/100 dilution. Serum Ig titers were determined by ELISA (Pierce, Rockland, IL, or PharMingen, San Diego, CA). Statistical significance was evaluated by paired Student’s t test on mean Ig titers or autoantibody OD values. FANA comparisons utilized t test on proportions.

Cell analyses

Spleens and six peripheral nonmesenteric lymph nodes were weighed, homogenized, and cleared of erythrocytes by osmotic lysis. Live cell count was determined by trypan blue exclusion. For phenotypic analyses, cells were analyzed by FACSort flow cytometry and CellQuest 1.1 software (Becton Dickinson, Bedford, MA): Abs included H129.19 FITC or PE (anti-CD4), GL3 PE (anti-TCR-{gamma}{delta}), RA3-6B2 biotin (anti-CD45R/B220), H57-597 FITC, or PE (anti-TCR-ß; all from PharMingen), and/or 53-6.7 Quantum Red (anti-CD8{alpha}; Sigma Chemical Co.), followed by streptavidin-Texas Red (Life Technologies).

Histopathology

Tissue specimens were fixed in 10% buffered Formalin, and sections were stained with hematoxylin and eosin by standard procedures at Department of Pathology, Yale University School of Medicine (15, 16, 35, 36). Disease was evaluated on a 0 to 4 scale in renal glomeruli, tubules, and perivascular regions; salivary gland acini and perivascular regions; and hepatic periportal regions. The degree and histopathologic character of lymphoid infiltrates were evaluated in kidney, liver, and salivary gland sections. Immunofluorescent studies were performed onOCT-embedded frozen sections, as described (35, 36), using FITC- and/or PE-conjugated 145-2C11 (anti-CD3)CD3), H129.19 (anti-CD4), 53-6.7 (anti-CD8{alpha}), RA3-6B2 (anti-B220), H57-597 (anti-TCR Cß), RR8-1 (anti-TCR V{alpha}11b,d), B20.6 (anti-TCR Vß2), RR4-7 (anti-Vß6), MR5-2 (anti-TCR Vß8.1/Vß8.2), 1B3.3 (anti-TCR Vß8.3), B21.5 (anti-TCR Vß10b), 14-2 (anti-TCR Vß14), and PE-conjugated KJ25 (anti-Vß3; all from PharMingen). Immune deposit analyses utilized FITC-conjugated polyclonal goat anti-mouse IgG (Sigma Chemical Co.). All immunofluorescent photographs were taken on ASA 400 film at an exposure time of 8 s.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Generation of pfp-/- lupus-prone mice

Pfp-/- (41) animals were crossed once against MRL/lpr breeders, generating pfp+/- Fas+/lpr offspring. These F1 animals were intercrossed to generate pfp+/+ (pfp+) or pfp-/- (pfp-), Fas+/+ (Fas+), or lpr/lpr (lpr) F2 animals, generating four genotypic groups of similar genetic backgrounds (approximately 50% MRL). Since previous studies have demonstrated the dominance of MRL autoimmunity-inducing genes in genetic crosses (34, 35, 47, 48), the background of these animals conveys a lupus-like autoimmune phenotype. Indeed, the disease of these mice can be considered representative of typical MRL murine lupus, as indicated by their production of hypergammaglobulinemia, specific autoantibodies, and end-organ disease (34, 35, 48, and see below). PCR-assayed genotypes were confirmed by flow cytometry for Fas staining, as well as by NK cytotoxicity assay: consistently, NK cell-enriched splenocytes from pfp- animals failed to lyse pfp-sensitive YAC-1 cells, whereas those from pfp+ animals successfully achieved as high as 40% specific target cell lysis, using E:T ratios varying from 40:1 to 1.25:1, regardless of Fas genotype (Fig. 1Go and data not shown).



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 1. Cytotoxicity activity of pfp-deficient mice. NK-enriched splenocytes from three pfp+ and three pfp- animals were used as effectors against 51Cr-labeled YAC-1 target cells. In contrast to pfp+ cells, pfp- cells consistently lacked cytotoxic activity, as assayed by 51Cr release. The data here are representative of three similar experiments using both Fas+ and lpr cells; error bars represent SDs.

 
Survival of pfp- lupus-prone mice

Notably, the median survival of pfp-lpr animals (n = 8) was only 8 wk, whereas pfp+lpr animals (n = 12) had a median survival of 24 wk (p < 0.001), typical of most hybrid MRL lupus strains (30, 34, 36, 47, 48). In contrast, all nine pfp+Fas+ and nine pfp-Fas+ animals survived beyond 32 wk of age.

Abnormal lymphoaccumulation in pfp-lpr mice

The accelerated mortality of pfp-lpr mice was most likely explained by uncontrolled lymphoaccumulation that afflicted their kidneys, livers, and salivary glands, as well as lymphoid organs (Table IGo and Figs. 2Go–4). In all organs examined, pfp-lpr mice had substantial organ destruction by a monomorphic, atypical lymphoid infiltrate, characterized by enlarged, vesicular nuclei with indistinct nucleoli and irregular nuclear contours (Fig. 2Go and data not shown). Occasional small mature lymphocytes were scattered throughout such lesions. In salivary glands, only rare residual acini and salivary ducts remained (Fig. 2GoH and data not shown), while in kidneys and livers, similar infiltrates were restricted predominantly in a perivascular location with a lesser degree of interstitial involvement (Fig. 2Go, G and J, respectively, and data not shown). These infiltrates were highly reminiscent of lpr-induced lymphoaccumulative disease.


View this table:
[in this window]
[in a new window]
  		Table I. End-organ disease in perforin-deficient lupus-prone mice

 


View larger version (123K):
[in this window]
[in a new window]
  		FIGURE 2. End-organ disease in perforin-deficient mice. A, Renal tissues in pfp+Fas+ animals were typically normal or occasionally had perhaps mild glomerular hypercellularity, as seen in this 12-wk-old specimen. Age-matched pfp-Fas+ animals and 8-mo-old pfp+Fas+ animals had kidneys with similarly negligible histologic findings. B, Both pfp+Fas+ and pfp-Fas+ animal groups also had grossly normal salivary gland histology, as seen in this 12-wk-old pfp+Fas+ tissue. Eight-month-old pfp-Fas+ animals, however, developed moderate glomerular disease with mild-moderate interstitial and perivascular infiltrates, as demonstrated by a specimen with glomerulonephritis and mild periglomerular reaction (C); and also developed moderate sialoadenitis consisting of destructive lesions of acini as well as perivascular infiltrates (D). Pfp+lpr animals consistently developed severe renal and salivary gland disease, which was evident in both organs by 12 wk of age: mesangial proliferation and hypercellularity, as well as mild interstitial infiltrates, were typically seen in kidneys (E), and perivasculitis and acinar infiltration were typically seen in salivary glands (F). Renal perivasculitis was also evident (not shown). Twelve-week-old pfp-lpr mice displayed (H) diffuse replacement of the salivary gland by an atypical lymphoid infiltrate that left only rare salivary acini and ducts. Smaller perivascular infiltrates with identical cytology were present in the kidney (G) and liver (J), with focal extension into the parenchyma. I, Most pfp+Fas+ animals had grossly normal hepatic histology, but occasionally had mild periportal infiltrates, as seen in this 12-wk-old specimen. Numbers of animals examined histologically were 3, 3, 3, 4, 3, 3, and 2 for the pfp+Fas+ 12 wk, pfp-Fas+ 12 wk, pfp+lpr 12 wk, pfp-lpr 12 wk, pfp+Fas+ 8 mo, pfp-Fas+ 8 mo, and pfp+lpr 8 mo groups, respectively. Scale bar, 25 µm.

 
In contrast, kidneys, salivary glands, and livers from pfp+lpr mice revealed only limited and variable parenchymal lymphoid infiltrates, again in a perivascular pattern, but consisting of a polymorphous lymphoplasmacytic population, typical of MRL/lpr autoimmune disease (Fig. 2Go, E and F, and data not shown) (12, 13, 14). Although mildly enlarged lymphocytes were present, the cytologic atypia seen in pfp-lpr animals was uniformly lacking. The atypical cells in pfp-lpr animals were {alpha}ß+CD3+CD4-CD8-B220- T cells, as determined directly by immunofluorescence on frozen tissue sections and indirectly by flow cytometry on cell suspensions from spleen and lymph nodes (p < 0.001; Figs. 3Go and 4 and data not shown; note the expansion of a TCR--{alpha}ß+CD4-CD8-B220- T cell subset in pfp-lpr compared with pfp+lpr lymph nodes). In comparison, the infiltrates of pfp+lpr mice consisted predominantly of CD3-B220+ B cells, although CD3+B220- and CD3+B220+ T cells were occasionally seen. Thus, pfp contributes to the regulation of cellular homeostasis in lpr animals.



View larger version (61K):
[in this window]
[in a new window]
  		FIGURE 3. Immunofluorescence characterization of pfp-deficient lpr infiltrates. A, Negative background fluorescence of an infiltrate from a pfp+lpr animal stained with anti-Vß14 Ab (scale bar, 10 µm). Pfp-lpr infiltrates were characterized as predominately TCR-{alpha}ß+CD3+CD4-CD8-B220-B, Here, a predominantly Vß14+ area is shown, which stained for occasional Vß8.1/Vß8.2+ cells (scale bar, 25 µm), and C, many Vß14 cells (scale bar, 10 µm). Immunohistologic analyses were performed from animals at 12 wk of age; these results are representative of 3, 3, 3, and 4 animals examined for the pfp+Fas+, pfp-Fas+, pfp+lpr, and pfp-lpr groups, respectively. Kidney infiltrates are shown here.

 
Accelerated autoimmunity in pfp-Fas+mice

In contrast, Fas-intact animals required pfp primarily to regulate humoral and end-organ autoimmune disease. Pfp-Fas+ animals had more hypergammaglobulinemia, higher levels of autoantibodies, and more severe end-organ disease than their pfp+Fas+ counterparts (Tables I-III, Figs. 5Go–7, and data not shown). At 3 mo of age, pfp-Fas+ mice had higher titers of IgM, IgG1, IgG2a, and IgG2b than pfp+Fas+ counterparts (p < 0.001), and 8-mo-old animals maintained higher levels of IgM, IgG1, and IgG2b (p < 0.005; Table IIIGo and Fig. 5Go). Similarly, pfp-Fas+ animals also developed higher levels of autoantibodies: at both 3 and 8 mo of age, they contained higher levels of rheumatoid factor and anti-snRNP Abs (p < 0.01), and at 8 mo of age, they contained higher levels of anti-dsDNA Abs (p < 0.01; Fig. 6Go). In addition, all nine of nine 8-mo-old pfp-Fas+ animals tested positive for antinuclear Abs, in comparison with only five of nine pfp+Fas+ animals (p < 0.001). In contrast, no clear differences in serum Ig and autoantibody titers were observed between pfp-lpr and pfp+lpr animals, which developed higher levels of hypergammaglobulinemia, particularly of the IgG2a and IgG3 isotypes (p < 0.001), and autoantibodies, particularly antinuclear Abs and rheumatoid factor (p < 0.001), compared with Fas+ animals.



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 5. Serum Igs in pfp-deficient mice. Sera were assayed for Ig isotype titers by ELISA. Note that the two remaining pfp+lpr animals that were available for analysis at 31 wk of age most likely reflect milder disease than typical for pfp+lpr disease, since their median survival was only 24 wk in this study. Numbers of animals examined for Ig synthesis were 12, 12, 12, 4, 9, 9, and 2 for the pfp+Fas+ 12 wk, pfp-Fas+ 12 wk, pfp+lpr 12 wk, pfp-lpr 12 wk, pfp+Fas+ 8 mo, pfp-Fas+ 8 mo, and pfp+lpr 8 mo groups, respectively, as described in Table IIIGo. Note the use of logarithmic scale.

 

View this table:
[in this window]
[in a new window]
  		Table III. Mean serum Igs in perforin-deficient lupus-prone mice1

 


View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 6. Autoantibody production by pfp-deficient mice. Sera were assayed for antinuclear Abs by the indirect antinuclear Ab test (FANA). Specific autoantibodies were tested by specific ELISA for IgG anti-dsDNA, IgG anti-snRNP, and {kappa} rheumatoid factor titers. Normals include B10.BR and/or RAG-1-/- mice. Note that the two remaining pfp+lpr animals that were available for analysis at 31 wk of age most likely reflect milder disease than typical for pfp+lpr disease, since their median survival was only 24 wk in this study. Numbers of animals examined for autoantibodies were as described in Table IIIGo and this figure.

 
End-organ disease in pfp-Fas+ animals primarily consisted of more intense light-microscopic disease of kidneys and salivary glands in comparison with pfp+Fas+ counterparts (Table IGo and Fig. 2Go and data not shown). Although all Fas+ animals at 3 mo of age had only mild or absent end-organ disease, pfp+Fas+ animals at 8 mo of age developed mild glomerular disease and occasionally mild perivascular infiltrates in salivary glands. Age-matched pfp-Fas+ animals, however, consistently contained more glomerular, interstitial, and perivascular renal lesions and/or infiltrates, as well as greater acinar damage and perivascular infiltrates in salivary glands. Hepatic infiltrates also appeared more common and perhaps more intense among pfp-Fas+ animals as compared with pfp+Fas+ counterparts, even though disease remained generally mild among all Fas+ animals. Notably, pfp+lpr animals developed renal, salivary gland, and hepatic lesions typical of MRL/lpr autoimmune disease, including glomerulonephritis, interstitial infiltrates, and perivasculitis in kidneys; acinar atrophy with periductal and perivascular infiltrates in salivary glands; and mild-moderate periportal infiltrates in livers.

The accelerated end-organ disease of pfp-Fas+ animals most likely resulted from increased immune complex-related formation secondary to accelerated humoral autoimmunity, since their renal lesions consistently contained greater immune deposits, as assayed by immunofluorescent studies (Table IIGo and Fig. 7Go). Pfp-Fas+ animals generally had diffuse capillary wall and mesangial immune deposits affecting all glomeruli, significantly more prominent than their pfp+Fas+ counterparts. The former also had more significant tubular basement membrane as well as occasional intranuclear staining, which were not apparent in pfp+Fas+ specimens. By comparison, both pfp+lpr and pfp-lpr animals developed severe diffuse mesangial and capillary wall deposits as well as glomerular collapse, consistent with their proliferative glomerulonephritis, and also developed tubular and intranuclear deposits as well.


View this table:
[in this window]
[in a new window]
  		Table II. Renal Ig deposition in perforin-deficient lupus-prone mice1

 


View larger version (97K):
[in this window]
[in a new window]
  		FIGURE 7. Renal immune deposits in pfp-deficient lupus-prone mice. A, Pfp+Fas+ kidneys generally contained negligible immune deposits. B, Age-matched, pfp-Fas+ kidneys, however, contained mild glomerular and tubular immune deposits, with mild antinuclear Ab staining. Pfp+lpr kidneys (C) and pfp-lpr kidneys (D) contained substantial glomerular, tubular, and usually antinuclear immune deposits, typical of MRL/lpr immune complex glomerulonephritis (14, 17, 18, 34, 35). Analyses were performed from animals at 12 wk of age; these results are representative of 3, 3, 3, and 4 mice for the pfp+Fas+, pfp-Fas+, pfp+lpr, and pfp-lpr groups, respectively. Photographs were taken on ASA 400 film at an exposure time of 8 s. Scale bar, 25 µm.

 
Of note, overall cell populations were largely unaffected by pfp deficiency, particularly in Fas+ animals (Fig. 4Go). Comparable spleen and lymph node weights and cell counts were found between pfp+Fas+ vs pfp-Fas+ animals, as well as between pfp+lpr vs pfp-lpr animals. Furthermore, pfp+ animals also contained numbers of {alpha}ß T cells, {gamma}{delta} T cells, and B cells (B220+{alpha}ß-{gamma}{delta}- cells) similar to pfp- animals, comparing pfp+Fas+ with pfp-Fas+ animals, as well as pfp+lpr with pfp-lpr animals.



View larger version (52K):
[in this window]
[in a new window]
  		FIGURE 4. Cell populations in pfp-deficient mice. Spleens and six peripheral nonmesenteric lymph nodes were weighed, and their cells were counted. Lymph node cells were further analyzed by flow cytometry for B cell, {gamma}{delta} T cell, and {alpha}ß T cell populations; the latter was further analyzed by CD4, CD8, and B220 staining, demonstrating the expansion of CD4-CD8-B220- {alpha}ß T cells in pfp-lpr vs pfp+lpr mice. Comparable findings were found among spleens of the same animals (not shown). In the lower right panel, {alpha}ß T cells were B220-, unless specified as expressing this marker. Analyses were performed from animals at 12 wk of age; these results are representative of 3, 3, 3, and 4 animals for the pfp+Fas+, pfp-Fas+, pfp+lpr, and pfp-lpr groups, respectively. Note the use of logarithmic scale in the two upper and lower left panels.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
This study has demonstrated a protective role for pfp in murine lupus. Pfp-lpr mice developed significantly more lymphoaccumulation than their pfp+lpr counterparts, although hypergammaglobulinemia, autoantibody production, immune complex renal disease, and lymphadenopathy were grossly similar. In comparison, pfp-Fas+ animals developed significantly higher degrees of hypergammaglobulinemia, autoantibodies, and end-organ disease than pfp+Fas+ animals. Relatively small numbers of animals were examined in each genotypic group, perhaps making broad, definitive conclusions regarding the regulation of autoimmunity difficult. Nevertheless, these findings provide evidence that cytotoxic interactions down-regulate systemic autoimmune processes, in contrast to the pathogenic roles of cognate Th cells (19, 20, 21), and specifically identify pfp as a mechanism for such regulation. Of note, the results obtained in this study do not simply reflect a stochastic effect of the various genetic backgrounds on disease penetrance, since the four groups of mice used in this study each consisted of approximately 50% MRL genes, creating comparable autoimmune-prone, lymphoproliferation-prone genetic environments for all groups. Consequently, the effects of pfp- and/or Fas- deficiency seen in this study most likely reflect underlying processes characteristic to this background (34).

The findings in Fas-intact animals indicate a significant role for pfp in the regulation of systemic humoral autoimmunity and the consequent development of end-organ disease. Pfp may play a direct role in the regulation of autoreactive B cells by T cells or NK cells, such that pfp deficiency results in increased generalized autoreactive B cell hyperactivity, which previously has been suggested as pathogenic in murine lupus models (49, 50, 51). Pfp appears subordinate to that of Fas in the regulation of autoreactive B cells, however, since pfp deficiency did not result in humoral and end-organ disease similar to lpr disease; indeed, the grossly unchanged lymphocyte populations in pfp-Fas+ animals (Fig. 4Go) argue against an overt regulatory defect in the T cell or B cell lineages. Rather, Fas-dependent regulation of B cells by T cells (31, 32, 33) or by NK cells (52, 53) most likely helps to prevent otherwise severe autoimmunity in pfp-Fas+ animals. As an alternative, pfp may provide a mechanism by which regulatory T cells, either {alpha}ß and/or {gamma}{delta} (22, 34, 35, 36), eliminate activated, pathogenic {alpha}ß T cells (22, 34).

The acceleration of end-organ disease in spite of relatively preserved humoral autoimmune parameters in pfp-lpr animals reinforces a role for pfp in cellular regulation, and suggests that pfp primarily regulates autoreactive T cells, rather than B cells, at least in the setting of Fas deficiency. Accordingly, autoreactive B cell activation appeared unchanged in pfp-lpr animals, as assayed by B cell counts, hypergammaglobulinemia, autoantibodies, and renal immune deposits, in comparison with the acceleration of autoimmunity by pfp deficiency in Fas+ animals. Indeed, Fas may be the primary mechanism by which B cells are regulated (31, 32, 33, 52, 53), and thus, pfp deficiency may not significantly affect lpr B cells. On the other hand, lpr T cells appear to rely heavily upon pfp for self-surveillance in the absence of Fas-Fas ligand interactions, resulting in T cell lymphoaccumulation in double-deficient states, even though other, tertiary pathways for cytotoxicity most likely remain (54). Alternatively, if pfp acts via other immune cell populations, such as NK cells, cellular effects may similarly predominate over humoral effects due to the roles of these cell types in primarily cellular immune effects, such as Ab-dependent or complement-mediated cytotoxicity.

Such considerations raise interest in the origin of the T cells that comprise the lymphoaccumulation syndromes of both pfp+lpr and pfp-lpr animals. Pfp deficiency may simply exacerbate lpr disease, such that the defective activation-induced cell death characteristic of lpr T cells is simply further propagated in double-deficient animals, resulting in the lymphoaccumulation of multiple autoreactive T cell clones previously stimulated by autoantigen(s) (3, 4, 5, 6). Pfp may also, however, play a role in the regulation of T cells undergoing different types of immune responses, such as during infection or tumor progression, such that combined pfp and Fas deficiency result in global dysregulation of ongoing immune responses. For example, the T cell infiltration in pfp-lpr animals may actually reflect an additional reactive lymphoproliferation to a distinct underlying malignancy, such as the hyperproliferation of atypical, clonal T cells in response to underlying EBV-induced B cell lymphoma in lymphomatoid granulomatosis (55, 56, 57), as suggested by the presence of a T cell-regulated B cell lymphoma in lpr animals (36). These considerations may be relevant to tumor progression in settings of immunodeficiency, such as AIDS, in which defective lymphocyte-mediated suppression may permit the development of malignant lymphoma (58, 59).

These demonstrations of the importance of cytotoxic mechanisms in systemic autoimmunity also provide new directions of study for therapeutic interventions. Traditional approaches have involved global down-regulation of the immune system, such as by anti-inflammatory drugs, corticosteroids, or antimetabolic agents (60, 61). The acceleration of autoimmunity in both TNF-deficient (12) and pfp-deficient lupus-prone animals (this study) strongly suggests that particular lymphocyte subsets provide significant regulatory functions that may be enhanced by specific therapeutic techniques. The identification and utilization of such cells will be of substantial interest to future investigations.


   Acknowledgments
 
We thank Tom Taylor for assistance with flow cytometry.


   Footnotes
 
1 This work was supported in part by grants from National Institutes of Health (AR40072 and AR44076) and from the Arthritis and Lupus Foundations, their Connecticut chapters, and donations to Yale Rheumatology in the memories of Irene Feltman, Albert L. Harlow, and Chantal Marquis (to J.C.). S.L.P. was supported by Medical Scientist Training Program, Yale University School of Medicine. Back

2 Address correspondence and reprint requests to Dr. Joe Craft, P.O. Box 208031, LCI 609, 333 Cedar Street, New Haven, CT 06520-8031. E-mail address: Back

3 Abbreviations used in this paper: pfp, perforin; FANA, fluorescent antinuclear Ab; PE, phycoerythrin; snRNP, small nuclear ribonucleoprotein. Back

Received for publication February 19, 1997. Accepted for publication September 30, 1997.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Andrews, B. S., R. A. Eisenberg, A. N. Theofilopoulos, S. Izui, C. B. Wilson, P. J. McConahey, E. D. Murphy, J. B. Roths, F. J. Dixon. 1978. Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J. Exp. Med. 148:1198.[Abstract/Free Full Text]
  2. Morse, H. C., W. F. III, R. A. Davidson, E. D. Yetter, J. B. Roths Murphy, R. L. Coffman. 1982. Abnormalities induced by the mutant gene lpr: expansion of a unique lymphocyte subset. J. Immunol. 129:2612.[Abstract]
  3. Singer, G. G., A. K. Abbas. 1994. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365.[Medline]
  4. Fisher, G. H., F. J. Rosenberg, S. E. Straus, J. K. Dale, L. A. Middleton, A. Y. Lin, W. Strober, M. J. Lenardo, J. M. Puck. 1995. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935.[Medline]
  5. Renno, T., M. Hahne, J. Tschopp, H. R. MacDonald. 1996. Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and up-regulate Fas and Fas ligand. J. Exp. Med. 183:431.[Abstract/Free Full Text]
  6. Van Parijs, L., A. Ibraghimov, A. K. Abbas. 1996. The roles of costimulation and fas in T cell apoptosis and peripheral tolerance. Immunity 4:321.[Medline]
  7. Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314.[Medline]
  8. Adachi, M., F. R. Watanabe, S. Nagata. 1993. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc. Natl. Acad. Sci. USA 90:1756.[Abstract/Free Full Text]
  9. Chu, J. L., J. Drappa, A. Parnassa, K. B. Elkon. 1993. The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J. Exp. Med. 178:723.[Abstract/Free Full Text]
  10. Kobayashi, S., T. Hirano, M. Kakinuma, T. Uede. 1993. Transcriptional repression and differential splicing of Fas mRNA by early transposon (ETn) insertion in autoimmune lpr mice. Biochem. Biophys. Res. Commun. 191:617.[Medline]
  11. Wu, J., T. Zhou, J. He, J. D. Mountz. 1993. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J. Exp. Med. 178:461.[Abstract/Free Full Text]
  12. Zhou, T., C. K. Edwards III, P. Yang, Z. Wang, H. Bluethmann, J. D. Mountz. 1996. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J. Immunol. 156:2661.[Abstract]
  13. Jonsson, R., A. Tarkowski, K. Backman, R. Holmdahl, L. Klareskog. 1987. Sialadenitis in the MRL-l mouse: morphological and immunohistochemical characterization of resident and infiltrating cells. Immunology 60:611.[Medline]
  14. Hewicker, M., G. Trautwein. 1986. Glomerular lesions in MRL mice: a light and immunofluorescence microscopic study. Zentralbl. Veterinaermed. [B] 33:727.
  15. Vlahakos, D. V., M. H. Foster, S. Adams, M. Katz, A. A. Ucci, K. J. Barrett, S. K. Datta, M. P. Madaio. 1992. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int. 41:1690.[Medline]
  16. Vlahakos, D., M. H. Foster, A. A. Ucci, K. J. Barrett, S. K. Datta, M. P. Madaio. 1992. Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J. Am. Soc. Nephrol. 2:1345.[Abstract]
  17. Hewicker, M., E. Kromschröder, G. Trautwein. 1989. Untersuchungen zur pathogenese der glomerulonephritis be MRL-Mäusen: muriner lupus erythematodes. Verh. Dtsch. Ges. Pathol. 73:129.[Medline]
  18. Hewicker, M., E. Kromschröder, G. Trautwein. 1990. Detection of circulating immune complexes in MRL mice with different forms of glomerulonephritis. Z. Verstierkd. 33:149.
  19. Santoro, T. J., J. P. Portanova, B. L. Kotzin. 1988. The contribution of L3T4+ T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice. J. Exp. Med. 167:1713.[Abstract/Free Full Text]
  20. Jevnikar, A. M., M. J. Grusby, L. H. Glimcher. 1994. Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice. J. Exp. Med. 179:1137.[Abstract/Free Full Text]
  21. Koh, D.-R., A. Ho, A. Rahemutulla, W.-P. Fung-Leung, H. Griesser, T.-W. Mak. 1995. Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. Eur. J. Immunol. 25:2558.[Medline]
  22. Peng, S. L., J. Craft. 1997. The regulation of murine lupus. Ann. NY Acad. Sci. 815:128.[Free Full Text]
  23. Mosmann, T. R., S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138.[Medline]
  24. Jacob, C. O., P. H. van der Meide, H. O. McDevitt. 1987. In vivo treatment of (NZB x NZW)F1 lupus-like nephritis with monoclonal antibody to {gamma} interferon. J. Exp. Med. 166:798.[Abstract/Free Full Text]
  25. Finck, B. K., B. Chan, D. Wofsy. 1994. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J. Clin. Invest. 94:585.
  26. Ishida, H., T. Muchamuel, S. Sakaguchi, S. Andrade, S. Menon, M. Howard. 1994. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179:305.[Abstract/Free Full Text]
  27. Ozmen, L., D. Roman, M. Fountoulakis, G. Schmid, B. Ryffel, G. Garotta. 1995. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-{gamma} receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 25:6.[Medline]
  28. Schorlemmer, H. U., G. Dickneite, E. J. Kanzy, K. H. Enssle. 1995. Modulation of the immunoglobulin dysregulation in GvH- and SLE-like diseases by the murine IL-4 receptor (IL-4-R). Inflamm. Res. 44:S194.
  29. Huang, F.-P., G.-J. Feng, G. Lindop, D. I. Stott, F. Y. Liew. 1996. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. J. Exp. Med. 183:1447.[Abstract/Free Full Text]
  30. Peng, S. L., J. Moslehi, J. Craft. 1997. Roles of interferon-{gamma} and interleukin-4 in murine lupus. J. Clin. Invest. 99:1936.[Medline]
  31. Rathmell, J. C., M. P. Cooke, W. Y. Ho, J. Grein, S. E. Townsend, M. M. Davis, C. C. Goodnow. 1995. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 376:181.[Medline]
  32. Rothstein, T. L., J. K. Wang, D. J. Panka, L. C. Foote, Z. Wang, B. Stanger, H. Cui, S. T. Ju, A. Marshak-Rothstein. 1995. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 374:163.[Medline]
  33. Scott, D. W., T. Grdina, Y. Shi. 1996. T cells commit suicide, but B cells are murdered!. J. Immunol. 156:2352.[Abstract]
  34. Peng, S. L., M. P. Madaio, A. C. Hayday, J. Craft. 1996. Propagation and regulation of systemic autoimmunity by {gamma}{delta} T cells. J. Immunol. 157:5689.[Abstract]
  35. Peng, S. L., M. P. Madaio, D. P. M. Hughes, I. N. Crispe, M. J. Owen, L. Wen, A. C. Hayday, J. Craft. 1996. Murine lupus in the absence of {alpha}ß T cells. J. Immunol. 156:4041.[Abstract]
  36. Peng, S. L., M. E. Robert, A. C. Hayday, J. Craft. 1996. A tumor suppressor function for fas (CD95) revealed in T cell-deficient mice. J. Exp. Med. 184:1149.[Abstract/Free Full Text]
  37. Lee, R. K., J. Spielman, D. Y. Zhao, K. J. Olsen, E. R. Podack. 1996. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J. Immunol. 157:1919.[Abstract]
  38. Kagi, D., B. Ledermann, K. Burki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31.[Medline]
  39. Kagi, D., F. Vignaux, B. Ledermann, K. Burki, V. Depraetere, S. Nagata, H. Hengartner, P. Golstein. 1994. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528.[Abstract/Free Full Text]
  40. Lowin, B., M. Hahne, C. Mattmann, J. Tschopp. 1994. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370:650.[Medline]
  41. Walsh, C. M., M. Matloubian, C. C. Liu, R. Ueda, C. G. Kurahara, J. L. Christensen, M. T. Huang, J. D. Young, R. Ahmed, W. R. Clark. 1994. Immune function in mice lacking the perforin gene. Proc. Natl. Acad. Sci. USA 91:10854.[Abstract/Free Full Text]
  42. Hammond, D. M., P. S. Nagarkatti, L. R. Gote, A. Seth, M. R. Hassuneh, M. Nagarkatti. 1993. Double-negative T cells from MRL-lpr/lpr mice mediate cytolytic activity when triggered through adhesion molecules and constitutively express perforin gene. J. Exp. Med. 178:2225.[Abstract/Free Full Text]
  43. Nakamura, T., I. Ebihara, Y. Tomino, K. Okumura, H. Koide. 1991. Perforin mRNA expression in the inflamed tissues of NZB/W F1 lupus mice decreases with methylprednisolone treatment. Am. J. Pathol. 139:731.[Abstract]
  44. Ueda, G., S. Hirose, T. Shirai. 1992. An early activation antigen of murine T cells recognized by monoclonal natural autoantibody NTA204 and the expression on T cells from aged NZB x NZW F1 mice with overt autoimmune disease. Autoimmunity 12:117.[Medline]
  45. Hughes, D. P. M., A. Hayday, J. E. Craft, M. J. Owen, I. N. Crispe. 1995. T cells with the {gamma}/{delta} T cell receptors (TCR) of intestinal type are preferentially expanded in TCR-{alpha}-deficient lpr mice. J. Exp. Med. 182:233.[Abstract/Free Full Text]
  46. Chadwick, B. S., R. G. Miller. 1992. Hybrid resistance in vitro: possible role of both class I MHC and self peptides in determining the level of target cell sensitivity. J. Immunol. 148:2307.[Abstract]
  47. Eisenberg, R. A., S. Y. Craven, C. L. Fisher, S. C. Morris, R. Rapoport, D. S. Pisetsky, P. L. Cohen. 1989. The genetics of autoantibody production in MRL/lpr lupus mice. Clin. Exp. Rheumatol. 7:S35.
  48. Shlomchik, M. J., M. P. Madaio, D. Ni, M. Trounstein, D. Huszar. 1994. The role of B cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 180:1295.[Abstract/Free Full Text]
  49. Perkins, D. L., R. M. Glaser, C. A. Mahon, J. Michaelson, A. Marshak-Rothstein. 1990. Evidence for an intrinsic B cell defect in lpr/lpr mice apparent in neonatal chimeras. J. Immunol. 145:549.[Abstract]
  50. Nemazee, D., C. Guiet, K. Buerki, A. Marshak-Rothstein. 1991. B lymphocytes from the autoimmune-prone mouse strain MLR/lpr manifest an intrinsic defect in tetraparental MRL/lpr in equilibrium DBA/2 chimeras. J. Immunol. 147:2536.[Abstract/Free Full Text]
  51. Sobel, E. S., T. Katagiri, K. Katagiri, S. C. Morris, P. L. Cohen, R. A. Eisenberg. 1991. An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J. Exp. Med. 173:1441.[Abstract/Free Full Text]
  52. Montel, A. H., M. R. Bochan, J. A. Hobbs, D. H. Lynch, Z. Brahmi. 1995. Fas involvement in cytotoxicity mediated by human NK cells. Cell. Immunol. 166:236.[Medline]
  53. Yamauchi, A., K. Taga, H. S. Mostowski, E. T. Bloom. 1996. Target cell-induced apoptosis of interleukin-2-activated human natural killer cells: roles of cell surface molecules and intracellular events. Blood 87:5127.[Abstract/Free Full Text]
  54. Braun, M. Y., B. Lowin, L. French, H. Acha-Orbea, J. Tschopp. 1996. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183:657.[Abstract/Free Full Text]
  55. Jr Guinee, D., E. Jaffe, D. Kingma, N. Fishback, K. Wallberg, J. Krishnan, G. Frizzera, W. Travis, M. Koss. 1994. Pulmonary lymphomatoid granulomatosis: evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am. J. Surg. Pathol. 18:753.[Medline]
  56. Myers, J. L., P. J. Kurtin, A. L. Katzenstein, H. D. Tazelaar, T. V. Colby, J. G. Strickler, R. V. Lloyd, P. G. Isaacson. 1995. Lymphomatoid granulomatosis: evidence of immunophenotypic diversity and relationship to Epstein-Barr virus infection. Am. J. Surg. Pathol. 19:1300.[Medline]
  57. Wilson, W. H., D. W. Kingma, M. Raffeld, R. E. Wittes, E. S. Jaffe. 1996. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood 87:4531.[Abstract/Free Full Text]
  58. Herndier, B. G., L. D. Kaplan, M. S. McGrath. 1994. Pathogenesis of AIDS lymphomas. AIDS 8:1025.[Medline]
  59. Levine, A. M.. 1994. AIDS-related malignancies. Curr. Opin. Oncol. 6:489.[Medline]
  60. Fox, D. A., W. J. McCune. 1994. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 20:265.[Medline]
  61. Alarcon-Segovia, D.. 1994. The treatment of systemic lupus erythematosus. Clin. Exp. Rheumatol. 12:S49.



This article has been cited by other articles:


Home page
 J. Immunol.Home page
R. Puliaev, I. Puliaeva, L. A. Welniak, A. E. Ryan, M. Haas, W. J. Murphy, and C. S. Via
CTL-Promoting Effects of CD40 Stimulation Outweigh B Cell-Stimulatory Effects Resulting in B Cell Elimination and Disease Improvement in a Murine Model of Lupus
J. Immunol., July 1, 2008; 181(1): 47 - 61.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. Mateo, M. Menager, G. de Saint-Basile, M.-C. Stolzenberg, B. Roquelaure, N. Andre, B. Florkin, F. le Deist, C. Picard, A. Fischer, et al.
Perforin-dependent apoptosis functionally compensates Fas deficiency in activation-induced cell death of human T lymphocytes
Blood, December 15, 2007; 110(13): 4285 - 4292.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Cerboni, A. Zingoni, M. Cippitelli, M. Piccoli, L. Frati, and A. Santoni
Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis
Blood, July 15, 2007; 110(2): 606 - 615.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Kaplan, Q. Lu, A. Wu, J. Attwood, and B. Richardson
Demethylation of Promoter Regulatory Elements Contributes to Perforin Overexpression in CD4+ Lupus T Cells
J. Immunol., March 15, 2004; 172(6): 3652 - 3661.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Bose, Y. Inoue, K. E. Kokko, and F. G. Lakkis
Cutting Edge: Perforin Down-Regulates CD4 and CD8 T Cell-Mediated Immune Responses to a Transplanted Organ
J. Immunol., February 15, 2003; 170(4): 1611 - 1614.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
N. M. Wulffraat, G. T. Rijkers, E. Elst, R. Brooimans, and W. Kuis
Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation
Rheumatology, February 1, 2003; 42(2): 375 - 379.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
O. T. M. Chan, V. Paliwal, J. M. McNiff, S.-H. Park, A. Bendelac, and M. J. Shlomchik
Deficiency in {beta}2-Microglobulin, But Not CD1, Accelerates Spontaneous Lupus Skin Disease While Inhibiting Nephritis in MRL-Faslpr Mice: An Example of Disease Regulation at the Organ Level
J. Immunol., September 1, 2001; 167(5): 2985 - 2990.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
M. J. Smyth, J. M. Kelly, V. R. Sutton, J. E. Davis, K. A. Browne, T. J. Sayers, and J. A. Trapani
Unlocking the secrets of cytotoxic granule proteins
J. Leukoc. Biol., July 1, 2001; 70(1): 18 - 29.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. K. Sandberg, N. M. Fast, and D. F. Nixon
Functional Heterogeneity of Cytokines and Cytolytic Effector Molecules in Human CD8+ T Lymphocytes
J. Immunol., July 1, 2001; 167(1): 181 - 187.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
V. ARNOLD, S. BALKOW, R. STAATS, H. MATTHYS, W. LUTTMANN, and J. C. VIRCHOW Jr.
Increase in Perforin-positive Peripheral Blood Lymphocytes in Extrinsic and Intrinsic Asthma
Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 182 - 186.
[Abstract] [Full Text]

Home page
 ScienceHome page
S. E. Stepp, R. Dufourcq-Lagelouse, F. L. Deist, S. Bhawan, S. Certain, P. A. Mathew, J. Henter, M. Bennett, A. Fischer, G. d. S. Basile, et al.
Perforin Gene Defects in Familial Hemophagocytic Lymphohistiocytosis
Science, December 3, 1999; 286(5446): 1957 - 1959.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
R. B. Smeltz, N. A. Wolf, and R. H. Swanborg
Inhibition of Autoimmune T Cell Responses in the DA Rat by Bone Marrow-Derived NK Cells In Vitro: Implications for Autoimmunity
J. Immunol., August 1, 1999; 163(3): 1390 - 1397.
[Abstract] [Full Text] [PDF]